PRO-203 SC / InnoCare, Keymed Biosciences, Prolium Bioscience - LARVOL DELTA

Prolium Bioscience Announces First Patient Dosed in its Multinational, Phase 1/2 Study of PRO-203 in Systemic Sclerosis… (Yahoo Finance) - "Phase 1/2 SSc study is expected to enroll patients at over 20 participating clinical sites in at least five countries...Data...SAD study will be shared at an upcoming medical meeting....The Phase 1/2 study (NCT07641634) is a two-part study of PRO-203, administered subcutaneously. Part 1, which consisted of a single ascending dose study in healthy adult volunteers, enrolled 20 participants at a single site in Australia and is now complete. Part 2 will enroll up to 24 patients with systemic sclerosis (SSc) across multiple dose cohorts to assess safety and preliminary efficacy."

Trial status • Systemic Sclerosis

InnoCare Releases 2024 Interim Results and Business Highlights (Businesswire) - P=NA | N=NA | "ICP-B02 is a CD20xCD3 bispecific antibody co-developed with Keymed. Data from both the intravenous infusion (IV) and the subcutaneous (SC) formulations have shown good efficacy of ICP-B02 in patients with follicular lymphoma (FL) and DLBCL. All 15 patients who were treated with ICP-B02 at doses ≥6mg achieved response, resulting in an ORR of 100%. All patients who achieved CR maintained the remission as of the cutoff date. Based on the encouraging results of ICP-B02 as a single agent, the Company is planning for a dose expansion study of ICP-B02 in combination with other immunochemotherapies targeting earlier lines of treatment in NHL patients."

Clinical data • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

SUBCUTANEOUS CM355, A NOVEL BISPECIFIC CD20/CD3 ANTIBODY SHOWED PROMISING EFFICACY AND FAVORABLE SAFETY PROFILE IN RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (EHA 2024) - P1/2 | "At the doses evaluated, CM355 SC demonstrated favorable safety profile and promising efficacy in patientswith R/R B-cell NHL. All CRS events were manageable with minimal intervention. Rapid and deep responses, aswell as the convenience of SC formulation, support further clinical development for treatment of B-cell NHL."

Clinical • Anemia • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20

InnoCare Releases 2022 Annual Results and Business Highlights (Businesswire) - "ICP-B02 (CM355): The IND application for ICP-B02 subcutaneous (SC) formulation was approved for clinical trial by the CDE in March 2023."

IND • Oncology